Sang-We Kim
Impact in
- Oncology top 0.1%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 102
- Lung Cancer Diagnosis and Treatment 18
- Oncology 75
- Lung Cancer Research Studies 27
- Cancer Immunotherapy and Biomarkers 19
- Colorectal Cancer Treatments and Studies 14
- HER2/EGFR in Cancer Research 7
- Co-authors
- Jung‐Shin Lee (24 shared papers)Myung‐Ju Ahn (15 shared papers)Ki Hyeong Lee (34 shared papers)Cheolwon Suh (47 shared papers)Dae Ho Lee (41 shared papers)Cheolwon Suh (6 shared papers)Keunchil Park (18 shared papers)Jin Seok Ahn (5 shared papers)
- Journals
- Journal of Thoracic Oncology (23 papers)Journal of Clinical Oncology (17 papers)Lung Cancer (13 papers)Cancer Research and Treatment (13 papers)Journal of Korean Medical Science (11 papers)
- Partner nations
- South KoreaUnited StatesJapan
In The Last Decade
Sang-We Kim
216 papers receiving 16.0k citations
Sang-We Kim's Hit Papers
Peers
Comparison fields: 5 of 120
- Oncology 8.6k
- Pulmonary and Respiratory Medicine 8.1k
- Cancer Research 1.5k
- Immunology 1.0k
- Genetics 437
Countries citing papers authored by Sang-We Kim
This map shows the geographic impact of Sang-We Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sang-We Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sang-We Kim more than expected).
Fields of papers citing papers by Sang-We Kim
This network shows the impact of papers produced by Sang-We Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sang-We Kim. The network helps show where Sang-We Kim may publish in the future.
Co-authors
The 25 scholars most cited alongside Sang-We Kim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 227 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2019 | 2191 |
| 2 | Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1711 |
| 3 | Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 1288 |
| 4 | First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung Hit paper breakdown → | 2012 | 660 |
| 5 | Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2020 | 516 |
| 6 | Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study Hit paper breakdown → | 2021 | 507 |
| 7 | Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial Hit paper breakdown → | 2017 | 496 |
| 8 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 496 |
| 9 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 492 |
| 10 | Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC Hit paper breakdown → | 2023 | 452 |
| 11 | Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Hit paper breakdown → | 2023 | 418 |
| 12 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study Hit paper breakdown → | 2022 | 328 |
| 13 | Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions Hit paper breakdown → | 2023 | 258 |
| 14 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial Hit paper breakdown → | 2023 | 256 |
| 15 | First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial Hit paper breakdown → | 2021 | 252 |
| 16 | Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC Hit paper breakdown → | 2024 | 250 |
| 17 | Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer Hit paper breakdown → | 2021 | 231 |
| 18 | Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial Hit paper breakdown → | 2023 | 217 |
| 19 | 2020 | 208 | |
| 20 | 2007 | 159 |
About Sang-We Kim
Sang-We Kim is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Hematology, Pathology and Forensic Medicine and Genetics, having authored 227 papers that have together received 16.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (102 papers), Lung Cancer Research Studies (27 papers), Cancer Immunotherapy and Biomarkers (19 papers), Lung Cancer Diagnosis and Treatment (18 papers), Colorectal Cancer Treatments and Studies (14 papers), Lymphoma Diagnosis and Treatment (14 papers), HER2/EGFR in Cancer Research (7 papers) and Multiple Myeloma Research and Treatments (7 papers). The work is most often cited by research in Oncology (8.6k citations), Pulmonary and Respiratory Medicine (8.1k citations), Cancer Research (1.5k citations), Immunology (1.0k citations) and Genetics (437 citations). Sang-We Kim has collaborated with scholars based in South Korea, United States and Japan. Frequent co-authors include Jung‐Shin Lee, Myung‐Ju Ahn, Ki Hyeong Lee, Cheolwon Suh, Dae Ho Lee, Cheolwon Suh, Keunchil Park, Jin Seok Ahn, Jae‐Won Lee and Ji‐Youn Han. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Lung Cancer, Cancer Research and Treatment and Journal of Korean Medical Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.